IQV IQVIA (IQV) Q2 FY26 earnings call
IQVIA delivered an outstanding Q2 FY26, exceeding guidance across key financial metrics driven by strong operational execution and improving market conditions. The company saw accelerated organic growth and robust R&D bookings, fueled by increasing demand in both clinical and commercial segments, particularly from emerging biopharma and strategic large pharma partnerships. Management raised full-year guidance, highlighting the continued momentum and the differentiating impact of its AI-enabled solutions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
IQV operating KPIs by quarter
| KPI | Dec 2024 Q4 FY24 | Mar 2025 Q1 FY25 | Jun 2025 Q2 FY25 | Sep 2025 Q3 FY25 | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|---|---|---|
| Net new bookings R&D Solutions | $2.5B+On the clinical side, net new bookings for the quarter were over $2.5 billion, and this all highlights the great work that was done by our R&DS team in securing new business contracts.Source: earnings call transcript | — | — | — | — | $2.5BOn this new basis, R&D Solutions net new bookings in Q1 2026 was $2.5 billion, a double-digit increase year-over-year.Source: earnings call transcript | — | — |
| Backlog R&D Solutions | $31.1BR&DS backlog at December 31 was $31.1 billion, an increase of 4.4% year-over-year and 5.5% at constant currency.Source: earnings call transcript | $31.5BR&DS backlog at March 31 was $31.5 billion, an increase of 4.8% year-over-year and 4.6% at constant currency.Source: earnings call transcript | $32.1BR&DS backlog at June 30 was $32.1 billion, an increase of 5.1% year-over-year.Source: earnings call transcript | $32.4BFinally, our backlog reached a new record of $32.4 billion at the end of the quarter showing growth of 4.1% compared to the prior year.Source: earnings call transcript | $32.7BBacklog reached a new record of $32.7 billion at the end of the quarter, growing 5.3% compared to the prior year.Source: earnings call transcript | $34.2BRDS backlog at March 31 was $34.2 billion, which is an increase of mid-single digit year-over-year.Source: earnings call transcript | $34.2BAs of June 30, R&DS backlog was $34.2 billion and the next 12-month revenue from this backlog was $9.230 billion which is up 7.5% versus last year.Source: earnings call transcript | 0% |
| Book-to-bill ratio | — | — | — | — | — | 1.04 ratioWhile our book-to-bill ratio 1.04 in the quarter despite solid service fee bookings growth and normal cancellations.Source: earnings call transcript | 1.22 ratioIf I may add, this 1.22 was in a quarter where our revenue was up almost 9% year-over-year, stronger than anticipated.Source: earnings call transcript | +17.3% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.